Canada medical device regulations

Current Health Canada guidance on how Class II-IV medical device licence applications are managed end to end, as one merged document from its 7-page family: filing (fees, submission channels, target performance standards), administrative/regulatory/technical screening, review (clarification requests, additional-information letters, pause-the-clock, refusal), refiling within and after 6 months, and the reconsideration process for refused applications, plus process-map appendices. Foreword document control: version 5, published 21 November 2025, effective 2 February 2026, replacing the 1 April 2020 edition. Ingested from the exact official HTML with a foreword preamble and continuous sec-1..sec-32 section anchors across part-1..part-7 (one part per page).

Section view of Schedule 1 Part 2 IVD classification rules. Official Schedule 2 is “Implants”; the previous Schedule 2 IVD label was corrected against the Justice Laws consolidated text.

Section view of SOR/98-282 labelling requirements including bilingual consumer-device labelling, manufacturer identification, and directions for use.

Section view of SOR/98-282 Part 1 establishment-licence provisions (ss. 44 to 51.1). MDEL requirements for manufacturers (Class I) and importers/distributors (all classes).

Section view of SOR/98-282 Part 1 Class II–IV medical device licence provisions. The previous “Part 2” label was incorrect: official Part 2 is custom-made and special-access devices.

Section view of SOR/98-282 incident-reporting and hospital-information provisions (ss. 59 to 62). Later shortage sections (62.21+) are not part of this view.

Primary regulation governing medical devices in Canada. Establishes classification (Class I-IV), licensing requirements, establishment licensing (MDEL), and post-market obligations. Official consolidated expression from Justice Laws; current to 17 June 2026.

Parent statute of the Canadian medical-device regime: the Food and Drugs Act defines "device" (s. 2) and establishes the offences, inspection, and regulation-making powers (s. 30) under which the Medical Devices Regulations (SOR/98-282) are made. Part I (Foods, Drugs, Cosmetics and Devices) carries the sale and advertising prohibitions, including prohibited advertising (s. 3) and prohibited sales of devices (s. 8); Part II is Administration and Enforcement. Official consolidated expression from Justice Laws in both official languages, current to 31 March 2025 (last amended 27 March 2025); 107 sections across Parts I and II plus Schedules A to H (Schedule A.1 inserted 2019).

Complete Health Canada labelling guidance for medical devices other than IVDs, walked regulation-by-regulation through Medical Devices Regulations sections 21-24 (label contents, outer package, bilingual s. 23 requirements, and electronic labelling conditions) plus the two appendices for soft/decorative contact lenses and menstrual tampons published on the same page. Foreword document control: adopted 12 June 2004, version date 15 June 2015 (replaces the 2014-06-12 version). The URL slug ("including-vitro-diagnostic-devices-appendices") is stale; the current page title governs. Ingested from the exact official HTML with a foreword preamble (document control block incl. change log) and sec-1..sec-5 section anchors.

Complete Health Canada labelling guidance for in vitro diagnostic devices: label and package-insert requirements walked element-by-element through MDR section 21(1)(a)-(j) (name, manufacturer, identifier, directions for use, performance characteristics, storage), outer-container requirements, sections 22-24 including bilingual accommodation under section 23, special considerations for blood glucose monitoring systems, and labelling for IVDDs containing explosive or corrosive materials. Foreword document control: date 22 April 2016, replacing the 1998/06/16 draft guidance. Ingested from the exact official HTML with a foreword preamble and sec-1..sec-7 section anchors.

Health Canada guidance on when a new medical device licence is required versus an amendment and how to complete each application type, as one merged document from its 6-page family: overview and policy objective, definitions (licence application types, regulatory activities and transactions), implementation guidance for new licences and amendments (including Dossier ID requests), references, and the Bisphenol A and Di(2-Ethylhexyl) Phthalate chemical-identity appendices. All six pages carry date modified 24 April 2026. Ingested from the exact official HTML with continuous sec-1..sec-12 section anchors across part-1..part-6 (one part per page).

Current Health Canada guidance interpreting "significant change" under Medical Devices Regulations s. 32, as one merged document from its 5-page family: purpose and policy statements, general principles (risk assessment, the four-corner principle, design verification and validation), types of changes (design, software, sterilization and sterile barrier packaging, materials, labelling, manufacturing processes and facilities, diagnostic ultrasound), and the process for significant changes (amendment applications), minor changes, and non-significant changes including recalls. Foreword document control: published 31 March 2026, all five pages carrying the same date; the guidance also exists as a consolidated official PDF, while these HTML pages stay the ingest source for citeable anchors. Ingested from the exact official HTML with a foreword preamble and continuous sec-1..sec-27 section anchors across part-1..part-5 (one part per page).

Health Canada MDSAP transition page, not a Justice Laws instrument. Left as discovery metadata; the program description is not ingested as regulation source text.